Locations

Ness Ziona, Israel

industry

Biotechnology

Size

51-200 employees

Stage

IPO

founded in

2015

BiomX is developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as Cystic Fibrosis, Inflammatory Bowel Disease, Atopic Dermatitis, and Colorectal Cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Something looks off?
Open jobs at BIOMx
This company does not have jobs relevant to this job board at this time.
To view all their jobs, visit their website.